

Indication	Sponsor Protocol Number NCT Number	Study Description	Investigator 24 Hour Contact Info	Study Coordinator Regular Business Hours Contact Info (Primary Coord. Listed First)	Sponsor Emergency Contact If local contacts are unavailable
RSV Vaccine (Adults ≥ 60)	Pfizer C3671013 NCT05035212	A Phase 3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults	Robin McKelvey, MD	Rich Tomasco Josh Borunda 541-766-2163	877-433-2619
Severe Asthma	GSK 206785 NIMBLE NCT04718389	A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab	Roland Solensky, MD 541-754-1150	Lisa Buchheit Josh Borunda 541-766-2163	(484) 868 2102
Type 2 Diabetes	Eli Lilly I8F-MC-GPHE NCT05433584	A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared with Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes (SURPASS-EARLY)	Brian Curtis, MD 541-754-1150	Rich Tomasco Josh Borunda 541-766-2163	317-651-8478
Type 2 Diabetes	Novo Nordisk NN9924-4635 Pioneer Plus NCT04707469	Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in subjects with type 2 diabetes	Brian Curtis, MD 541-754-1150	Rich Tomasco Josh Borunda 541-766-2163	+45 3079 9386
Obesity in Type 2 Diabetes	Eli Lilly I8F-MC-GPHL (SURMOUNT-2) NCT04657003	Efficacy and Safety of Tirzepatide Once Weekly in Participants with Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo Controlled Trial (SURMOUNT-2)	Brian Curtis, MD 541-754-1150	Kim Tally Josh Borunda 541-766-2163	416-557-6462

Indication	Sponsor Protocol Number NCT Number	Study Description	Investigator 24 Hour Contact Info	Study Coordinator Regular Business Hours Contact Info (Primary Coord. Listed First)	Sponsor Emergency Contact If local contacts are unavailable
Co-administration of Menveo and Bexsero Vaccines	GSK V72_79 NCT04318548	Safety and Immunogenicity Study of GSK Meningococcal Group B Vaccine <i>Bexsero</i> (GSK3536829A) when Administered Concomitantly with GSK Meningococcal MenACWY Conjugate Vaccine <i>Menveo</i> (GSK3536820A) to Healthy Subjects 16-18 Years of Age	Christy Rivers, DO 541-754-1150	Julie Carrico Josh Borunda 541-766-2163	877-870-0019
COVID Vaccine	Janssen Ensemble NCT04505722	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Brian Curtis, MD 541-754-1150	Rich Tomasco Josh Borunda 541-766-2163	(844) 551-8271
Cardiac Risk Reduction	Novo Nordisk EX9536-4388 NCT03574597	SELECT – Semaglutide effects on cardiovascular outcomes in people with overweight or obesity	Brian Curtis, MD 541-754-1150	Kim Tally Josh Borunda 541-766-2163	609-987-5817 or 609-902-0903